Skip to main content

Table 3 Results of subgroup analysis based on different standards

From: Diagnostic value of urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 for acute kidney injury: a meta-analysis

Study

 

Sensitivity (95% CI)

Specificity (95% CI)

PLR (95% CI)

NLR (95% CI)

DOR (95% CI)

AUC

Nine studies

 

0.83 (0.79–0.87)

0.55 (0.52–57)

2.37 (1.87–2.99)

0.30 (0.21–0.41)

9.92 (6.09–16.18)

0.846

I 2 (%)

 

68.8%

92.9%

82.6%

43.4%

38.5%

 

Population setting

Cardiac surgery (n = 4)

0.75 (0.62–0.86)

0.87 (0.80–0.92)

5.61 (3.54–8.89)

0.28 (0.12–0.67)

27.08 (9.87–74.34)

0.911

I 2 (%)

69.8%

33.9%

0.0%

59.7%

0.0%

 

ICU and ED (n = 5)

0.85 (0.80–0.89)

0.51 (0.49–0.54)

1.83 (1.58–2.13)

0.29 (0.20–0.41)

7.66 (4.79–12.24)

0.814

I 2 (%)

68.5%

89.2%

69.7%

35.7%

35.0%

 

AKI threshold

KDIGO stage 2 or 3 (n = 6)

0.88 (0.83–0.91)

0.52 (0.49–0.55)

1.92 (1.62–2.29)

0.25 (0.17–0.39)

8.04 (4.49–14.40)

0.813

I 2 (%)

38.9%

89.8%

74.3%

28.6%

43.1%

 

KDIGO stage 1 (n = 3)

0.70 (0.59–0.79)

0.88 (0.80–0.93)

5.20 (3.14–8.60)

0.37 (0.24–0.57)

17.04 (8.04–36.13)

0.868

I 2 (%)

54.3%

31.7%

0.0%

42.0%

0.0%

 

Blinding or not

Blinding (n = 6)

0.87 (0.82–0.91)

0.53 (0.51–0.56)

2.37 (1.83–3.08)

0.25 (0.18–0.34)

10.35 (6.83–15.70)

0.859

I 2 (%)

58.7%

93.7%

84.8%

0.0%

0.0%

 

Not blinding (n = 3)

0.73 (0.62–0.82)

0.59 (0.53–0.65)

3.78 (1.00–14.23)

0.42 (0.28–0.63)

9.98 (2.41–41.41)

0.838

I 2 (%)

59.0%

93.3%

84.9%

32.0%

68.4%

 
  1. Abbreviations: AKI Acute kidney injury, ICU Intensive care unit, ED Emergency department, PLR Positive likelihood ratio, NLR Negative likelihood ratio, DOR Diagnostic odds ratio, KDIGO Kidney Disease: Improving Global Outcomes